Should Plasma Homocysteine Be Used as a Biomarker of Venous Thromboembolism? A Case

Abstract

Mild or moderate hyperhomocysteinemia as a risk factor for venous thrombosis is still a matter of debate. The strength of this study is to bring a body of elements to evaluate whether hyperhomocysteinemia should be used as a biomarker for venous thromboembolism (VTE). These elements consist of a biological evaluation of several hematological risk factors, and an original control group made of patients with a negative Doppler ultrasonography. A total of 151 cases and 155 controls were included. Total plasma homocysteine level, MTHFR C677T polymorphism, inherited abnormalities of the natural anticoagulant system as well as plasma folate and cobalamin levels were determined. A total of 41 (27.2 %) of cases and only 9 (5.8%) of controls had at least one of the coagulation defects studied. No significant difference was observed for total homocysteine levels between the 2 groups: median (interquartile range) = 8.3 (7.2-10.8) μmol/L for cases and 8.4 (7-10.9) μmol/L for controls. We found significantly more plasma folates and/or cobalamin deficiencies in controls (18.3%) than in cases (8.6%). After adjustment for several variables significantly related to risk factors of VTE, hyperhomocysteinemia (>" xbd="2200" xhg="2176" ybd="1302" yhg="1257"/>13.2 μmol/L) was not found statistically associated with VTE: odds ratio 1.36 (95% confidence interval, 0.52-3.54). The prevalence of the homozygous 677TT polymorphism in the MTHFR gene was not increased in cases compared with controls. Mild or moderate hyperhomocysteinemia does not seem to be a strong determinant in VTE not only when the control group does not exclusively include healthy persons but also in investigated disease-free (thromboembolic disease) controls.

Keywords

venous thromboembolism homocysteine risk factor hyperhomocysteinemia

References

Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Thromb Haemost. 2000 ;83:657-660.

den Heijer M. , Koster T. , Blom HJ , et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996 ;334:759-762.

Ray JG Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med. 1998 ;158: 2101-2106.

Ridker PM , Hennekens CH , Selhub J. , Miletich JP , Malinow MR , Stampfer MJ Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation. 1997;95:1777-1782.

Fermo I. , Vigano’ D’Angelo S. , Paroni R. , Mazzola G. , Calori G. , and D’Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med. 1995;123:747-753.

Simioni P. , Prandoni P. , Burlina A. , et al. Hyperhomocysteinemia and deep-vein thrombosis. A case-control study. Thromb Haemost. 1996;76:883-886.

den Heijer M. , Rosendaal FR , Blom HJ , Gerrits WBJ , Bos GMJ. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost. 1998;80:874-877.

Langman LJ , Ray JG , Evrovski J. , Yeo E. , Cole DEC. Hyperhomocyst(e)inemia and the increased risk of venous thromboembolism: more evidence from a case-control study. Arch Intern Med. 2000;160:961-964.

den Heijer M. , Lewington S. , Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost. 2005;3:292-299.

10.

Amundsen T. , Ueland PM , Waage A. Plasma homocysteine levels in patients with deep venous thrombosis. Arterioscler Thromb Vasc Biol. 1995;15:1321-1323.

11.

Tsai AW , Cushman M. , Tsai MY , et al. Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Hematol. 2003;72:192-200.

12.

Brattstrom L. , Tengborn L. , Lagerstedt C. , Israelsson B. , Hultberg B. Plasma homocysteine in venous thromboembolism . Haemostasis. 1991;21:51-57.

13.

Lin JS , Shen MC , Cheng WC , et al. Age, sex and vitamin status affect plasma level of homocysteine, but hyperhomocysteinaemia is possibly not an important risk factor for venous thrombophilia in Taiwanese Chinese. Br J Haematol. 2002;117:159-163.

14.

Ducros V. , Schmitt D. , Pernod G. , Faure H. , Polack B. , Favier A. Gas chromatographic-mass spectrometric determination of total homocysteine in human plasma by stable isotope dilution: method and clinical applications . J Chromatogr B Biomed Sci Appl. 1999;729:333-339.

15.

Jacques PF , Selhub J. , Bostom AG , Wilson PW , Rosenberg IH The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999;340:1449-1454.

16.

Snow CF Laboratory diagnosis of vitamin B12 and folate deficiency. A guide for the primary care physician. Arch Intern Med. 1999 ;159:1289-1298.

17.

Quéré I. , Perneger TV , Zittoun J. , et al. Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study. Lancet. 2002 ;359:747-752.

18.

Cattaneo M. , Lombardi R. , Lecchi A. , Bucciarelli P. , Mannucci PM Low plasma levels of vitamin B(6) are independently associated with a heightened risk of deep-vein thrombosis. Circulation. 2001 ;104:2442-2446.

19.

Diaz de Tuesta AM , Ribo MD , Belinchon O. , et al. Low levels of vitamin B12 and venous thromboembolic disease in elderly men. J Intern Med. 2005;258: 244-249.

20.

Obeid R. , Hakki T. , Jouma M. , Hermann W. The risk of venous thromboembolism associated with the factor V Leiden mutation and low B-vitamin status. Clin Chem Lab Med. 2003;41:1357-1362.

21.

Cantu C. , Alonso E. , Jara A. , et al. Hyperhomocysteinemia, low folate and vitamin B12 concentrations, and methylene tetrahydrofolate reductase mutation in cerebral venous thrombosis . Stroke. 2004;35:1790-1794.

22.

Oger E. , Lacut K. , Le Gal G. , et al. Hyperhomocysteinemia and low vitamin levels are independently associated with venous thromboembolism: results from the EDITH study: a hospital-based case-control study. J Thromb Haemost. 2006 ;4:793-799.

23.

Friso S. , Jacques PF , Wilson PW , Rosenberg IH , Selhub J. Low circulating vitamin B(6) is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. Circulation. 2001;103:2788-2791.

24.

den Heijer M. , Willems HPJ. , Blom HJ , et al. Homocysteine lowering by B vitamins and the secondary prevention of deep-vein thrombosis and pulmonary embolism. A randomized, placebo-controlled, double blind trial . Blood . 2007;109:139-144.

25.

Ducros V. , Rousset J. , Garambois K. , et al. Hyperhomocystéinémie sévère révélant une homocystinurie chez deux adultes jeunes présentant un phénotype peu marqué [Severe hyperhomocysteinemia revealing homocystinuria in two young adults with mild phenotype]. Rev Med Int. 2006;27:140-143.

Should Plasma Homocysteine Be Used as a Biomarker of Venous Thromboembolism? A Case—Control Study

Abstract

Keywords

References